Judd W. Moul, MD
Director, Duke Prostate Center
James H. Semans, MD, Professor of Surgery
- Surgery / Urology
- Anesthesiology
Address
DUMC 3707
Durham, NC 27710
Appointment Telephone
919-668-8108
Office Telephone
919-684-5057
Fax Telephone
919-684-8794
- MD, Jefferson Medical College of Thomas Jefferson University (Pennsylvania), 1982
- Surgery, Walter Reed Army Medical Center (Washington, DC), 1982-1983
- Urology, Walter Reed Army Medical Center (Washington, DC), 1983-1987
- Urologic Oncology, Duke University Medical Center, 1988-1989
- Fellow, American College of Surgeons
Clinical Interests
Minimally invasive nerve-sparing radical prostatectomy, treatment of PSA-only or biochemical recurrence of prostate cancer, prostate cancer in African Americans, multidisciplinary management of prostate cancer, clinical trials in prostate disease, elevated PSA and screening, prostate cancer and outcomes/database research, elevated PSA and prostate cancer screening issues, active surveillance in early stage prostate cancer
This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
- Amgen, Inc.
- Best Doctors
- Dendreon Corporation
- IRIS Molecular Diagnostics (IRIS International)
- Janssen Pharmaceuticals (Johnson & Johnson)
- Platform Q Health Inc
- Sanofi-Aventis
- Theralogix LLC
- Up To Date Inc
Representative Publications
Boorjian, SA; Eastham, JA; Graefen, M; Guillonneau, B; Karnes, RJ; Moul, JW; Schaeffer, EM; Stief, C; Zorn, KC. A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. European Urology. 2012;61:664-675.
(2012)
Abstract
George, D; Moul, JW. Emerging treatment options for patients with castration-resistant prostate cancer. The Prostate. 2012;72:338-349.
(2012)
Abstract
Loeb, S; Carter, HB; Catalona, WJ; Moul, JW; Schroder, FH. Baseline prostate-specific antigen testing at a young age. European Urology. 2012;61:1-7.
(2012)
Abstract
Moul, JW. Prostate cancer: making the switch from LHRH antagonist to LHRH agonist. Nature Reviews Urology. 2012;9:125-126.
(2012)
Abstract
Moul, JW; Dawson, N. Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature. Cancer Investigation. 2012;30:1-12.
(2012)
Abstract
Schroeck, FR; Krupski, TL; Stewart, SB; Bañez, LL; Gerber, L; Albala, DM; Moul, JW. Pretreatment expectations of patients undergoing robotic assisted laparoscopic or open retropubic radical prostatectomy. Journal of Urology. 2012;187:894-898.
(2012)
Abstract
Stewart, SB; Bañez, LL; Robertson, CN; Freedland, SJ; Polascik, TJ; Xie, D; Koontz, BF; Vujaskovic, Z; Lee, WR; Armstrong, AJ; Febbo, PG; George, DJ; Moul, JW. Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center. Journal of Urology. 2012;187:103-108.
(2012)
Abstract
Tang, P; Du, W; Xie, K; Fu, J; Chen, H; Yang, W; Moul, JW. Characteristics of baseline PSA and PSA velocity in young men without prostate cancer: Racial differences. The Prostate. 2012;72:173-180.
(2012)
Abstract
Tsivian, M; Moreira, DM; Sun, L; Mouraviev, V; Kimura, M; Moul, JW; Polascik, TJ. Biopsy accuracy in identifying unilateral prostate cancer depends on prostate weight. Urologic Oncology: seminars and original investigations. 2012;30:21-25.
(2012)
Abstract
Wattson, DA; Chen, MH; Moul, JW; Moran, BJ; Dosoretz, DE; Robertson, CN; Polascik, TJ; Braccioforte, MH; Salenius, SA; D'Amico, AV. The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: implications for treatment selection. International Journal of Radiation: Oncology - Biology - Physics. 2012;82:e773-e779.
(2012)
Abstract
Arvold, ND; Chen, MH; Moul, JW; Moran, BJ; Dosoretz, DE; Bañez, LL; Katin, MJ; Braccioforte, MH; D'Amico, AV. Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease. Journal of Urology. 2011;186:91-96.
(2011)
Abstract
Chu, DI; De Nunzio, C; Gerber, L; Thomas, JA; Calloway, EE; Albisinni, S; Senocak, C; McKeever, MG; Moreira, DM; Tubaro, A; Moul, JW; Freedland, SJ; Bañez, LL. Predictive value of digital rectal examination for prostate cancer detection is modified by obesity. Prostate Cancer and Prostatic Diseases. 2011;14:346-353.
(2011)
Abstract
Cotter, SE; Chen, MH; Moul, JW; Lee, WR; Koontz, BF; Anscher, MS; Robertson, CN; Walther, PJ; Polascik, TJ; D'Amico, AV. Salvage radiation in men after prostate-specific antigen failure and the risk of death. Cancer. 2011;117:3925-3932.
(2011)
Abstract
Crawford, ED; Moul, JW; Rove, KO; Pettaway, CA; Lamerato, LE; Hughes, A. Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone. BJU International. 2011;108:1743-1749.
(2011)
Abstract
Dreicer, R; Bajorin, DF; McLeod, DG; Petrylak, DP; Moul, JW. New data, new paradigms for treating prostate cancer patients--VI: novel hormonal therapy approaches. Urology. 2011;78:S494-S498.
(2011)
Abstract
Fu, Q; Moul, JW; Sun, L. Contemporary radical prostatectomy. Prostate Cancer. 2011;2011:645030.
(2011)
Abstract
Moul, JW; Evans, CP; Gomella, LG; Roach, M; Dreicer, R. Traditional approaches to androgen deprivation therapy. Urology. 2011;78:S485-S493.
(2011)
Abstract
Reed, SD; Scales, CD; Stewart, SB; Sun, J; Moul, JW; Schulman, KA; Xu, J. Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer. Journal of Urology. 2011;185:841-847.
(2011)
Abstract
Tang, P; Sun, L; Uhlman, MA; Robertson, CN; Polascik, TJ; Moul, JW. Prostate-specific antigen velocity based risk-adapted discontinuation of prostate cancer screening in elderly men. BJU International. 2011;108:44-48.
(2011)
Abstract
Ali, A; Furusato, B; Ts'o, PO; Lum, ZP; Elsamanoudi, S; Mohamed, A; Srivastava, S; Moul, JW; Brassell, SA; Sesterhenn, IA; McLeod, DG. Assessment of circulating tumor cells (CTCs) in prostate cancer patients with low-volume tumors. Pathology International. 2010;60:667-672.
(2010)
Abstract
Caire, AA; Sun, L; Lack, BD; Lum, K; Tang, P; Stackhouse, DA; Robertson, CN; Mouraviev, V; Polascik, TJ; Albala, DM; Moul, JW. Predicting non-organ-confined prostate cancer in men diagnosed after 2000. Prostate Cancer and Prostatic Diseases. 2010;13:248-251.
(2010)
Abstract
Caire, AA; Sun, L; Polascik, TJ; Albala, DM; Moul, JW. Obese African-Americans with prostate cancer (T1c and a prostate-specific antigen, PSA, level of <10 ng/mL) have higher-risk pathological features and a greater risk of PSA recurrence than non-African-Americans. BJU International. 2010;106:1157-1160.
(2010)
Abstract
Caire, AA; Sun, L; Robertson, CN; Polascik, TJ; Maloney, KE; George, DJ; Price, MM; Stackhouse, DA; Lack, BD; Albala, DM; Moul, JW. Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75. Urology. 2010;75:1122-1127.
(2010)
Abstract
Caso, JR; Mouraviev, V; Tsivian, M; Polascik, TJ; Moul, JW. Prostate cancer: an evolving paradigm. Journal of Endourology. 2010;24:805-809.
(2010)
Abstract
Caso, JR; Tsivian, M; Mouraviev, V; Polascik, TJ; Moul, JW. Pathological T2 sub-divisions as a prognostic factor in the biochemical recurrence of prostate cancer. BJU International. 2010;106:1623-1627.
(2010)
Abstract
D'Amico, AV; Chen, MH; Sun, L; Lee, WR; Mouraviev, V; Robertson, CN; Walther, PJ; Polascik, TJ; Albala, DM; Moul, JW. Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death. BJU International. 2010;106:1618-1622.
(2010)
Abstract
Droz, JP; Balducci, L; Bolla, M; Emberton, M; Fitzpatrick, JM; Joniau, S; Kattan, MW; Monfardini, S; Moul, JW; Naeim, A; van Poppel, H; Saad, F; Sternberg, CN. Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Critical Reviews in Oncology Hematology. 2010;73:68-91.
(2010)
Abstract
Droz, JP; Balducci, L; Bolla, M; Emberton, M; Fitzpatrick, JM; Joniau, S; Kattan, MW; Monfardini, S; Moul, JW; Naeim, A; van Poppel, H; Saad, F; Sternberg, CN. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU International. 2010;106:462-469.
(2010)
Abstract
Jayachandran, J; Schroeck, F; Sun, L; Gerber, L; Moreira, DM; Moul, JW; Freedland, SJ. The Shared Equal Access Regional Cancer Hospital (SEARCH) nomogram for risk stratification in intermediate risk group of men with prostate cancer: validation in the Duke Prostate Center database. BJU International. 2010;105:180-184.
(2010)
Abstract
Moreira, DM; Presti, JC; Aronson, WJ; Terris, MK; Kane, CJ; Amling, CL; Sun, LL; Moul, JW; Freedland, SJ. The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. Prostate Cancer and Prostatic Diseases. 2010;13:87-93.
(2010)
Abstract
Moul, JW. Radiotherapy: Secondary malignancies after prostate cancer treatment. Nature Reviews. Clinical Oncology. 2010;7:249-250.
(2010)
Abstract
Moul, JW; Tang, P; Sun, L. Editorial comment on: Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts. European Urology. 2010;57:452.
(2010)
Abstract
Schroeck, FR; Kattan, MW; Moul, JW; Aronson, WJ; Presti, JC; Terris, MK; Kane, CJ; Amling, CL; Sun, L; Freedland, SJ. Re-calibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy. BJU International. 2010;105:1654-1659.
(2010)
Abstract
Tang, P; Sun, L; Uhlman, MA; Polascik, TJ; Freedland, SJ; Moul, JW. Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades: Duke University experience. Cancer. 2010;116:4711-4717.
(2010)
Abstract
Tang, P; Sun, L; Uhlman, MA; Robertson, CN; Polascik, TJ; Albala, DM; Donatucci, CF; Moul, JW. Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk. Journal of Urology. 2010;183:946-950.
(2010)
Abstract
Uhlman, MA; Sun, L; Stackhouse, DA; Caire, AA; Polascik, TJ; Robertson, CN; Madden, J; Vollmer, R; Albala, DM; Moul, JW. Tumor volume, tumor percentage involvement, or prostate volume: which is predictive of prostate-specific antigen recurrence?. Urology. 2010;75:460-466.
(2010)
Abstract
Uhlman, MA; Sun, L; Stackhouse, DA; Polascik, TJ; Mouraviev, V; Robertson, CN; Albala, DM; Moul, JW. Tumor percent involvement predicts prostate specific antigen recurrence after radical prostatectomy only in men with smaller prostate. Journal of Urology. 2010;183:997-1001.
(2010)
Abstract
Bañez, LL; Blake, GW; McLeod, DG; Crawford, ED; Moul, JW. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up. BJU International. 2009;104:310-314.
(2009)
Abstract
Bañez, LL; Sun, L; Trock, BJ; Han, M; Partin, AW; Aronson, WJ; Terris, MK; Presti, JC; Kane, CJ; Amling, CL; Moul, JW; Freedland, SJ. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy. Journal of Urology. 2009;182:491-496.
(2009)
Abstract
Caire, AA; Sun, L; Ode, O; Stackhouse, DA; Maloney, K; Donatucci, C; Mouraviev, V; Polascik, TJ; Robertson, CN; Albala, DM; Moul, JW. Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes?. Urology. 2009;74:643-647.
(2009)
Abstract
Chen, VH; Mouraviev, V; Mayes, JM; Sun, L; Madden, JF; Moul, JW; Polascik, TJ. Utility of a 3-dimensional transrectal ultrasound-guided prostate biopsy system for prostate cancer detection. Technology in Cancer Research and Treatment. 2009;8:99-104.
(2009)
Abstract
Chino, J; Schroeck, FR; Sun, L; Lee, WR; Albala, DM; Moul, JW; Koontz, BF. Robot-assisted laparoscopic prostatectomy is not associated with early postoperative radiation therapy. BJU International. 2009;104:1496-1500.
(2009)
Abstract
D'Alonzo, RC; Gan, TJ; Moul, JW; Albala, DM; Polascik, TJ; Robertson, CN; Sun, L; Dahm, P; Habib, AS. A retrospective comparison of anesthetic management of robot-assisted laparoscopic radical prostatectomy versus radical retropubic prostatectomy. Journal of Clinical Anesthesia. 2009;21:322-328.
(2009)
Abstract
Freedland, SJ; Bañez, LL; Sun, LL; Fitzsimons, NJ; Moul, JW. Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database. Prostate Cancer and Prostatic Diseases. 2009;12:259-263.
(2009)
Abstract
Habib, AS; Polascik, TJ; Weizer, AZ; White, WD; Moul, JW; ElGasim, MA; Gan, TJ. Lidocaine patch for postoperative analgesia after radical retropubic prostatectomy. Anesthesia and Analgesia. 2009;108:1950-1953.
(2009)
Abstract
Moul, JW. Innovations in urology from military medicine. Urologic Oncology: seminars and original investigations. 2009;27:551-552.
(2009)
Abstract
Moul, JW. Post-radical prostatectomy management options for positive surgical margins: argument for observation. Urologic Oncology: seminars and original investigations. 2009;27:92-96.
(2009)
Abstract
Moul, JW. Report from Durham. Prostate Cancer and Prostatic Diseases. 2009;12:209-210.
(2009)
Abstract
Moul, JW. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer. Cancer. 2009;115:3376-3378.
(2009)
Abstract
Moul, JW. Twenty-five year evolution of medical hormonal therapy for prostate cancer. BJU International. 2009;103:145-146.
(2009)
Abstract
Moul, JW. Will the global economic downturn affect prostate cancer care? Pelvic lymphadenectomy as an example. European Urology. 2009;55:1266-1268.
(2009)
Abstract
Moul, JW; Mouraviev, V; Sun, L; Schroeck, FR; Polascik, TJ. Prostate cancer: the new landscape. Current Opinion in Urology. 2009;19:154-160.
(2009)
Abstract
Nguyen, PL; Chen, MH; Catalona, WJ; Moul, JW; Sun, L; D'Amico, AV. Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. International Journal of Radiation: Oncology - Biology - Physics. 2009;73:659-664.
(2009)
Abstract
Polascik, TJ; Mayes, JM; Schroeck, FR; Sun, L; Madden, JF; Moul, JW; Mouraviev, V. Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy. Cancer. 2009;115:2104-2110.
(2009)
Abstract
Stackhouse, DA; Sun, L; Schroeck, FR; Jayachandran, J; Caire, AA; Acholo, CO; Robertson, CN; Albala, DM; Polascik, TJ; Donatucci, CF; Maloney, KE; Moul, JW. Factors predicting prostatic biopsy Gleason sum under grading. Journal of Urology. 2009;182:118-122.
(2009)
Abstract
Sun, L; Caire, AA; Robertson, CN; George, DJ; Polascik, TJ; Maloney, KE; Walther, PJ; Stackhouse, DA; Lack, BD; Albala, DM; Moul, JW. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. Journal of Urology. 2009;182:2242-2248.
(2009)
Abstract
Tsivian, M; Sun, L; Mouraviev, V; Madden, JF; Mayes, JM; Moul, JW; Polascik, TJ. Changes in Gleason score grading and their effect in predicting outcome after radical prostatectomy. Urology. 2009;74:1090-1093.
(2009)
Abstract
Xu, DD; Sun, SD; Wang, F; Sun, L; Stackhouse, D; Polascik, T; Albala, DM; Moul, JW; Caire, A; Robertson, CN. Effect of age and pathologic Gleason score on PSA recurrence: analysis of 2911 patients undergoing radical prostatectomy. Urology. 2009;74:654-658.
(2009)
Abstract
Demark-Wahnefried, W; Polascik, TJ; George, SL; Switzer, BR; Madden, JF; Ruffin, MT; Snyder, DC; Owzar, K; Hars, V; Albala, DM; Walther, PJ; Robertson, CN; Moul, JW; Dunn, BK; Brenner, D; Minasian, L; Stella, P; Vollmer, RT. Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiology, Biomarkers and Prevention. 2008;17:3577-3587.
(2008)
Abstract
Freedland, SJ; Sun, L; Kane, CJ; Presti, JC; Terris, MK; Amling, CL; Moul, JW; Aronson, WJ. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. BJU International. 2008;102:969-974.
(2008)
Abstract
Habib, AS; White, WD; El Gasim, MA; Saleh, G; Polascik, TJ; Moul, JW; Gan, TJ. Transdermal nicotine for analgesia after radical retropubic prostatectomy. Anesthesia and Analgesia. 2008;107:999-1004.
(2008)
Abstract
Isariyawongse, BK; Sun, L; Bañez, LL; Robertson, C; Polascik, TJ; Maloney, K; Donatucci, C; Albala, D; Mouraviev, V; Madden, JF; Moul, JW. Significant discrepancies between diagnostic and pathologic Gleason sums in prostate cancer: the predictive role of age and prostate-specific antigen. Urology. 2008;72:882-886.
(2008)
Abstract
Moul, JW. Are we overtreating prostate cancer?. Journal of Urology. 2008;180:2299-2300.
(2008)
Abstract
Moul, JW. Point: radical prostatectomy is the treatment of choice for high-risk prostate cancer patients. Brachytherapy. 2008;7:277-279.
(2008)
Abstract
Moul, JW. Report from Durham. Prostate Cancer and Prostatic Diseases. 2008;11:1.
(2008)
Abstract
Moul, JW. Report from Durham. Prostate Cancer and Prostatic Diseases. 2008;11:211.
(2008)
Abstract
Moul, JW. Words of wisdom. Re: obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. European Urology. 2008;54:232-233.
(2008)
Abstract
Moul, JW; Wu, H; Sun, L; McLeod, DG; Amling, C; Donahue, T; Kusuda, L; Sexton, W; O'Reilly, K; Hernandez, J; Chung, A; Soderdahl, D. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. Journal of Urology. 2008;179:S53-S59.
(2008)
Abstract
Mouraviev, V; Broadwater, G; Sun, L; Mayes, JM; Moul, JW; Polascik, TJ. Can prostate-specific antigen and prostate-specific antigen velocity be used for prostate cancer screening in men older than 70 years?. Urology. 2008;71:1020-1023.
(2008)
Abstract
Polascik, TJ; Mayes, JM; Sun, L; Madden, JF; Moul, JW; Mouraviev, V. Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. The Prostate. 2008;68:1380-1386.
(2008)
Abstract
Rampersaud, EN; Sun, L; Moul, JW; Madden, J; Freedland, SJ. Percent tumor involvement and risk of biochemical progression after radical prostatectomy. Journal of Urology. 2008;180:571-576.
(2008)
Abstract
Scales, CD; Antonelli, J; Curtis, LH; Schulman, KA; Moul, JW. Prostate-specific antigen screening among young men in the United States. Cancer. 2008;113:1315-1323.
(2008)
Abstract
Schroeck, FR; Donatucci, CF; Smathers, EC; Sun, L; Albala, DM; Polascik, TJ; Moul, JW; Krupski, TL. Defining potency: a comparison of the International Index of Erectile Function short version and the Expanded Prostate Cancer Index Composite. Cancer. 2008;113:2687-2694.
(2008)
Abstract
Schroeck, FR; Krupski, TL; Sun, L; Albala, DM; Price, MM; Polascik, TJ; Robertson, CN; Tewari, AK; Moul, JW. Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy. European Urology. 2008;54:785-793.
(2008)
Abstract
Schroeck, FR; Sun, L; Freedland, SJ; Albala, DM; Mouraviev, V; Polascik, TJ; Moul, JW. Comparison of prostate-specific antigen recurrence-free survival in a contemporary cohort of patients undergoing either radical retropubic or robot-assisted laparoscopic radical prostatectomy. BJU International. 2008;102:28-32.
(2008)
Abstract
Schroeck, FR; Sun, L; Freedland, SJ; Jayachandran, J; Robertson, CN; Moul, JW. Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy. Prostate Cancer and Prostatic Diseases. 2008;11:371-376.
(2008)
Abstract
Schroeck, FR; de Sousa, CA; Kalman, RA; Kalia, MS; Pierre, SA; Haleblian, GE; Sun, L; Moul, JW; Albala, DM. Trainees do not negatively impact the institutional learning curve for robotic prostatectomy as characterized by operative time, estimated blood loss, and positive surgical margin rate. Urology. 2008;71:597-601.
(2008)
Abstract
Weinrich, SP; Seger, RE; Rao, GS; Chan, EC; Hamm, RM; Godley, PA; Moul, JW; Powell, IJ; Chodak, GW; Taylor, KL; Weinrich, MC. A decision aid for teaching limitations of prostate cancer screening. Journal of National Black Nurses' Association. 2008;19:1-11.
(2008)
Abstract
Whittemore, DE; Hick, EJ; Carter, MR; Moul, JW; Miranda-Sousa, AJ; Sexton, WJ. Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens. Journal of Urology. 2008;179:516-522.
(2008)
Abstract
Bañez, LL; Hamilton, RJ; Partin, AW; Vollmer, RT; Sun, L; Rodriguez, C; Wang, Y; Terris, MK; Aronson, WJ; Presti, JC; Kane, CJ; Amling, CL; Moul, JW; Freedland, SJ. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA: Journal of the American Medical Association. 2007;298:2275-2280.
(2007)
Abstract
Burnett, AL; Aus, G; Canby-Hagino, ED; Cookson, MS; D'Amico, AV; Dmochowski, RR; Eton, DT; Forman, JD; Goldenberg, SL; Hernandez, J; Higano, CS; Kraus, S; Liebert, M; Moul, JW; Tangen, C; Thrasher, JB; Thompson, I; American Urological Association Prostate Cancer Guideline Update Panel. Erectile function outcome reporting after clinically localized prostate cancer treatment. Journal of Urology. 2007;178:597-601.
(2007)
Abstract
Cookson, MS; Aus, G; Burnett, AL; Canby-Hagino, ED; D'Amico, AV; Dmochowski, RR; Eton, DT; Forman, JD; Goldenberg, SL; Hernandez, J; Higano, CS; Kraus, SR; Moul, JW; Tangen, C; Thrasher, JB; Thompson, I. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. Journal of Urology. 2007;177:540-545.
(2007)
Abstract
D'Amico, AV; Chen, MH; Catalona, WJ; Sun, L; Roehl, KA; Moul, JW. Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. Cancer. 2007;110:56-61.
(2007)
Abstract
Fitzsimons, NJ; Sun, L; Moul, JW. Medical technologies for the diagnosis of prostate cancer. Expert Review of Medical Devices. 2007;4:227-239.
(2007)
Abstract
Fitzsimons, NJ; Sun, LL; Dahm, P; Moul, JW; Madden, J; Gan, TJ; Freedland, SJ. A single-institution comparison between radical perineal and radical retropubic prostatectomy on perioperative and pathological outcomes for obese men: an analysis of the Duke Prostate Center database. Urology. 2007;70:1146-1151.
(2007)
Abstract
Freedland, SJ; Moul, JW. Prostate specific antigen recurrence after definitive therapy. Journal of Urology. 2007;177:1985-1991.
(2007)
Abstract
Moul, JW. Timely diagnosis of testicular cancer. Urologic Clinics of North America. 2007;34:109-117.
(2007)
Abstract
Moul, JW; Bañez, LL; Freedland, SJ. Rising PSA in nonmetastatic prostate cancer. Oncology. 2007;21:1436-1445.
(2007)
Abstract
Moul, JW; Sun, L; Hotaling, JM; Fitzsimons, NJ; Polascik, TJ; Robertson, CN; Dahm, P; Anscher, MS; Mouraviev, V; Pappas, PA; Albala, DM. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. Journal of Urology. 2007;177:499-503.
(2007)
Abstract
Mouraviev, V; Mayes, JM; Sun, L; Madden, JF; Moul, JW; Polascik, TJ. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer. 2007;110:906-910.
(2007)
Abstract
Mouraviev, V; Nosnik, I; Sun, L; Robertson, CN; Walther, P; Albala, D; Moul, JW; Polascik, TJ. Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience. Urology. 2007;69:311-314.
(2007)
Abstract
Mouraviev, V; Sun, L; Madden, JF; Mayes, JM; Moul, JW; Polascik, TJ. Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy. Urology. 2007;70:1141-1145.
(2007)
Abstract
Nosnik, IP; Gan, TJ; Moul, JW. Open radical retropubic prostatectomy 2007: the true minimally invasive surgery for localized prostate cancer?. Expert Review of Anticancer Therapy: an essential contribution to decision making in cancer care. 2007;7:1309-1317.
(2007)
Abstract
Robinson, MR; Moul, JW. Novel techniques for the treatment of localized prostate cancer: evidence of efficacy?. Current Urology Reports. 2007;8:203-210.
(2007)
Abstract
Scales, CD; Curtis, LH; Norris, RD; Schulman, KA; Dahm, P; Moul, JW. Relationship between body mass index and prostate cancer screening in the United States. Journal of Urology. 2007;177:493-498.
(2007)
Abstract
Scales, CD; Moul, JW; Curtis, LH; Elkin, EP; Hughes, ME; Carroll, PR; CaPSURE Investigators. Prostate cancer in the Baby Boomer generation: results from CaPSURE. Urology. 2007;70:1162-1167.
(2007)
Abstract
Sun, L; Moul, JW; Hotaling, JM; Rampersaud, E; Dahm, P; Robertson, C; Fitzsimons, N; Albala, D; Polascik, TJ. Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years. British Journal of Urology (BJU) International. 2007;99:753-757.
(2007)
Abstract
Thompson, I; Thrasher, JB; Aus, G; Burnett, AL; Canby-Hagino, ED; Cookson, MS; D'Amico, AV; Dmochowski, RR; Eton, DT; Forman, JD; Goldenberg, SL; Hernandez, J; Higano, CS; Kraus, SR; Moul, JW; Tangen, CM; AUA Prostate Cancer Clinical Guideline Update Panel. Guideline for the management of clinically localized prostate cancer: 2007 update. Journal of Urology. 2007;177:2106-2131.
(2007)
Abstract
Tseng, TY; Cancel, QV; Fesperman, SF; Kuebler, HR; Sun, L; Robertson, CN; Polascik, TJ; Moul, JW; Vieweg, J; Albala, DM; Dahm, P. The role of early adopter bias for new technologies in robot assisted laparoscopic prostatectomy. Journal of Urology. 2007;177:1318-1323.
(2007)
Abstract
Anscher, MS; Clough, R; Robertson, CN; Prosnitz, LR; Dahm, P; Walther, P; Donatucci, CF; Albala, DM; Febbo, P; George, DJ; Sun, L; Moul, JW. Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate. Prostate Cancer and Prostatic Diseases. 2006;9:254-260.
(2006)
Abstract
Efstathiou, JA; Chen, MH; Catalona, WJ; McLeod, DG; Carroll, PR; Moul, JW; Roehl, KA; D'Amico, AV. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. Urology. 2006;68:342-347.
(2006)
Abstract
Freedland, SJ; Krupski, TL; Moul, JW. Update on outcomes research databases in prostate cancer 2006. Current Opinion in Urology. 2006;16:168-172.
(2006)
Abstract
Lee, WR; Moul, JW. Can prostate-specific antigen nadir predict prostate cancer outcomes following radiotherapy?. Nature Clinical Practice Oncology. 2006;3:534-535.
(2006)
Abstract
Merseburger, AS; Hennenlotter, J; Simon, P; Müller, CC; Kühs, U; Knüchel-Clarke, R; Moul, JW; Stenzl, A; Kuczyk, MA. Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions. Oncology Reports: an international journal devoted to fundamental and applied research in oncology. 2006;16:79-83.
(2006)
Abstract
Moul, JW. Treatment of PSA only recurrence of prostate cancer after prior local therapy. Current Pharmaceutical Design. 2006;12:785-798.
(2006)
Abstract
Moul, JW; Ward, JF. Management of the patient with a rising PSA alone. Hematology / Oncology Clinics of North America. 2006;20:897-908.
(2006)
Abstract
Scales, CD; Curtis, LH; Norris, RD; Schulman, KA; Albala, DM; Moul, JW. Prostate specific antigen testing in men older than 75 years in the United States. Journal of Urology. 2006;176:511-514.
(2006)
Abstract
Sun, M; Srikantan, V; Ma, L; Li, J; Zhang, W; Petrovics, G; Makarem, M; Strovel, JW; Horrigan, SG; Augustus, M; Sesterhenn, IA; Moul, JW; Chandrasekharappa, S; Zou, Z; Srivastava, S. Characterization of frequently deleted 6q locus in prostate cancer. DNA and Cell Biology. 2006;25:597-607.
(2006)
Abstract
Tseng, TY; Sevilla, DW; Moul, JW; Maloney, KE. Prostatic carcinosarcoma 15 years after combined external beam radiation and brachytherapy for prostatic adenocarcinoma: a case report. Prostate Cancer and Prostatic Diseases. 2006;9:195-197.
(2006)
Abstract
Xu, LL; Sun, C; Petrovics, G; Makarem, M; Furusato, B; Zhang, W; Sesterhenn, IA; McLeod, DG; Sun, L; Moul, JW; Srivastava, S. Quantitative expression profile of PSGR in prostate cancer. Prostate Cancer and Prostatic Diseases. 2006;9:56-61.
(2006)
Abstract
Bañez, LL; Srivastava, S; Moul, JW. Proteomics in prostate cancer. Current Opinion in Urology. 2005;15:151-156.
(2005)
Abstract
Brassell, SA; Kao, TC; Sun, L; Moul, JW. Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer. Urology. 2005;66:1229-1233.
(2005)
Abstract
Cooperberg, MR; Moul, JW; Carroll, PR. The changing face of prostate cancer. Journal of Clinical Oncology. 2005;23:8146-8151.
(2005)
Abstract
Dahm, P; Yang, BK; Salmen, CR; Moul, JW; Gan, TJ. Radical perineal prostatectomy for the treatment of localized prostate cancer in morbidly obese patients. Journal of Urology. 2005;174:131-134.
(2005)
Abstract
Gu, Y; Kim, KH; Ko, D; Srivastava, S; Moul, JW; McLeod, DG; Rhim, JS. Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line. Anticancer Research: international journal of cancer research and treatment. 2005;25:1-8.
(2005)
Abstract
Moul, JW. Screening for prostate cancer in military populations. Military Medicine: international journal of AMSUS. 2005;170:905-914.
(2005)
Abstract
Moul, JW; Saad, F. Low-risk prostate cancer patient: active treatment. Canadian Journal of Urology. 2005;12 Suppl 2:25-27.
(2005)
Abstract
Moul, JW; Zlotta, AR. Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy. British Journal of Urology (BJU) International. 2005;95:285-290.
(2005)
Abstract
Petrovics, G; Liu, A; Shaheduzzaman, S; Furusato, B; Sun, C; Chen, Y; Nau, M; Ravindranath, L; Chen, Y; Dobi, A; Srikantan, V; Sesterhenn, IA; McLeod, DG; Vahey, M; Moul, JW; Srivastava, S. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene. 2005;24:3847-3852.
(2005)
Abstract
Semmes, OJ; Feng, Z; Adam, BL; Banez, LL; Bigbee, WL; Campos, D; Cazares, LH; Chan, DW; Grizzle, WE; Izbicka, E; Kagan, J; Malik, G; McLerran, D; Moul, JW; Partin, A; Prasanna, P; Rosenzweig, J; Sokoll, LJ; Srivastava, S; Srivastava, S; Thompson, I; Welsh, MJ; White, N; Winget, M; Yasui, Y; Zhang, Z; Zhu, L. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clinical Chemistry (Washington, DC): international journal of molecular diagnostics and laboratory medicine. 2005;51:102-112.
(2005)
Abstract
Stewart, AJ; Scher, HI; Chen, MH; McLeod, DG; Carroll, PR; Moul, JW; D'Amico, AV. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. Journal of Clinical Oncology. 2005;23:6556-6560.
(2005)
Abstract
Ward, JF; Moul, JW. Biochemical recurrence after definitive prostate cancer therapy. Part I: defining and localizing biochemical recurrence of prostate cancer. Current Opinion in Urology. 2005;15:181-186.
(2005)
Abstract
Ward, JF; Moul, JW. Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer. Current Opinion in Urology. 2005;15:187-195.
(2005)
Abstract
Ward, JF; Moul, JW. Rising prostate-specific antigen after primary prostate cancer therapy. Nature Reviews: Urology. 2005;2:174-182.
(2005)
Abstract
Ward, JF; Moul, JW. Treating the biochemical recurrence of prostate cancer after definitive primary therapy. Clinical Prostate Cancer. 2005;4:38-44.
(2005)
Abstract
Zhou, P; Chen, MH; McLeod, D; Carroll, PR; Moul, JW; D'Amico, AV. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. Journal of Clinical Oncology. 2005;23:6992-6998.
(2005)
Abstract
